HOTH THERAPEUTICS ENTERS INTO EXPANDED SPONSORED RESEARCH AGREEMENT WITH THE GEORGE WASHINGTON UNIVERSITY FOR DERMATOLOGY TREATMENT CANDIDATE WEG232
WEG232 IS A TOPICAL TREATMENT WITH SPECIFIC SUBSTANCE P-RECEPTOR INHIBITOR FOR ERLOTINIB-INDUCED FACIAL DERMATITIS AND HAIR LOSS IN CANCER PATIENTS
NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
(PRNewsfoto/Hoth Therapeutics Inc.)
The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW. Hoth intends to request a Pre-IND meeting with the FDA by year-end.
Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.
Future studies will include:
Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.
